Vectors production center
Tools for Restorative and Regenerative Medicine


The CPV offers a translational viral vector development service from the proof of concept to pre-clinical vector production intended to use for toxicology studies. Since 1996, the vector core has developed processes for production and characterization of viral vectors derived    from adeno-associated virus (AAV) serotypes-1 to rh10 and Adenovirus at research grade.  The R&D group is focusing on the development of new production tools, production and   purification processes for clinical grade viral vectors, as well as Quality Controls for clinical applications. These developments are intended to be transferred to pharmaceutical platform   for production and characterization of clinical lots.


Specific technologies

  • 14 microbiological security stations II
  • 21 CO2 incubators
  • Nano Icellis bioreactors
  • Suspension cell culture in bioreactors
  • P3 and double door autoclave
  • Liquid chromatograph chains


Collaboration modalities

The platform is accessible to academic research units and companies.